понедельник, 8 февраля 2016 г.

RXi Pharmaceuticals Corp (RXII) Upgraded to "Buy" at Zacks Investment Research

RXi Pharmaceuticals Corp (RXII) Upgraded to "Buy" at Zacks Investment Research


The brokerage currently has a $0.25 price target on the biotechnology company's stock. Zacks Investment Research 's price objective would indicate a potential downside of 13.67% from the company's current price.



from Biotech News